Robert Lechleider - Seagen Senior Vice President - Clinical Development

SGENDelisted Stock  USD 228.74  0.19  0.08%   

President

Dr. Robert J. Lechleider M.D. serves as Senior Vice President Clinical Development of the Company. Robert J. Lechleider M.D. recently joined Seattle Genetics as Senior Vice President Clinical Development. Previously Dr. Lechleider held key roles at several biopharmaceutical companies including MacroGenics and MedImmune. Before joining the biotechnology industry he served as Assistant Professor of Pharmacology at Uniformed Services University of the Health Sciences and Associate Professor of Cell Biology at Georgetown University Medical School since 2016.
Tenure 8 years
Professional MarksPh.D
Phone425 527 4000
Webhttps://www.seagen.com
Lechleider received his A.B. cum laude from Princeton University and his M.D. from the University of Illinois College of Medicine at Chicago. He received clinical training in internal medicine at Beth Israel Hospital in Boston and in medical oncology at the National Cancer Institute in Bethesda. He was also a Howard Hughes Medical Institute Scholar and a Damon RunyonWalter Winchell postdoctoral fellow.

Seagen Management Efficiency

The company has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2793) %, meaning that it created substantial loss on money invested by shareholders. Seagen's management efficiency ratios could be used to measure how well Seagen manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 43.47 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Seagen Inc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seagen until it has trouble settling it off, either with new capital or with free cash flow. So, Seagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seagen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seagen to invest in growth at high rates of return. When we think about Seagen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records

PRESIDENT Age

Michele HolcombCardinal Health
52
Sally CurleyCardinal Health
N/A
Brian RiceCardinal Health
57
Pat FinanBlueScope Steel Limited
N/A
Patricia EnglishCardinal Health
44
Mark CaranoInsteel Industries
54
James PetelleInsteel Industries
74
Amy RockCumberland Pharmaceuticals
N/A
Leo PavlivCumberland Pharmaceuticals
54
Lisa CapodiciCardinal Health
N/A
Stephen FalkCardinal Health
49
Patricia MorrisonCardinal Health
58
Meghan FitzGeraldCardinal Health
44
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. Seagen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2675 people. Seagen Inc (SGEN) is traded on NASDAQ Exchange in USA and employs 3,256 people.

Management Performance

Seagen Inc Leadership Team

Elected by the shareholders, the Seagen's board of directors comprises two types of representatives: Seagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seagen. The board's role is to monitor Seagen's management team and ensure that shareholders' interests are well served. Seagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Roger Dansey, Chief Medical Officer
Vaughn Himes, Executive VP of Process Sciences and Technical Operations
Daniel Welch, Independent Director
Felix Baker, Lead Independent Director
Nancy Simonian, Independent Director
Peggy Pinkston, IR Contact Officer
Charles Romp, Ex US
MS JD, Chief Officer
Darren Cline, Executive Vice President - Commercial
Eric Dobmeier, COO, Corporate Secretary
Todd Simpson, CFO and Principal Accounting Officer
Pinkston Peggy, Senior Director - Corporate Communications
David Gryska, Independent Director
David Caouette, VP Communications
Srinivas Akkaraju, Independent Director
Alpna Seth, Director
Matt Skelton, VP Marketing
Marc Lippman, Independent Director
Jonathan Drachman, Chief Medical Officer and Executive Vice President Research and Development
Jean Liu, Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Robert Lechleider, Senior Vice President - Clinical Development
Christopher Pawlowicz, Ex HR
Clay Siegall, Co-Founder, Chairman, CEO and Pres
Robin Taylor, Chief Commercial Officer
Dennis Benjamin, Senior Vice President - Translational Research
Roger MD, Pres RD
John Orwin, Director
John McLaughlin, Independent Director

Seagen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Seagen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Seagen's short interest history, or implied volatility extrapolated from Seagen options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
Note that the Seagen Inc information on this page should be used as a complementary analysis to other Seagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Consideration for investing in Seagen Stock

If you are still planning to invest in Seagen Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seagen's history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk